Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glutarate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.50 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.50 |
| ▸ | BBOX1 | O75936 | 3/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | FABP3 | P05413 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutarate SCHEMBL3687196 | 0.92 | CA1 (0.58) | CA1HDAC3HDAC1HDAC2HDAC8 | |
| Glutarate SCHEMBL1035895 | 0.92 | — | — | |
| Glutarate SCHEMBL1740443 | 0.92 | CA1 (0.58) | CA1HDAC3HDAC1HDAC2HDAC8 | |
| Glutarate SCHEMBL3686349 | 0.92 | CA1 (0.58) | CA1HDAC3HDAC1HDAC2HDAC8 | |
| Glutarate SCHEMBL104914 | 0.92 | CA1 (0.58) | CA1HDAC3HDAC1HDAC2HDAC8 | |
| Glutarate SCHEMBL3688894 | 0.92 | CA1 (0.58) | CA1HDAC3HDAC1HDAC2HDAC8 | |
| Glutarate SCHEMBL1533372 | 0.92 | CA1 (0.58) | CA1HDAC3HDAC1HDAC2HDAC8 | |
| Glutarate SCHEMBL4520000 | 0.92 | CA1 (0.58) | CA1HDAC3HDAC1HDAC2HDAC8 | |
| Glutarate SCHEMBL3142978 | 0.92 | CA1 (0.58) | CA1HDAC3HDAC1HDAC2HDAC8 | |
| Glutarate SCHEMBL5134529 | 0.92 | CA1 (0.58) | CA1HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-8609616-B2 | Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions | OSTEOLOGIX A/S (DK) | 2013-12-17 | — | — | US | claimed |
| US-20130071496-A1 | CONTROLLED RELEASE COMPOSITION CONTAINING A STRONTIUM SALT | OSTEOLOGIX A/S (DK) | 2013-03-21 | — | — | US | claimed |
| EP-2416756-A2 | STABLE PHARMACEUTICAL COMPOSITIONS WITH HIGH BIOAVAILIBILITY | Bilgic, Mahmut (TR) | 2012-02-15 | — | — | EP | claimed |
| US-20110269675-A1 | STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS | OSTEOLOGIX A/S | 2011-11-03 | — | — | US | claimed |
| EP-2266584-A2 | Composition with strontium and vitamin D for the prophylaxis and/or treatment of cartilage and/or bone conditions | Osteologix A/S (DK) | 2010-12-29 | — | — | EP | claimed |
| EP-1732575-B1 | STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS | OSTEOLOGIX AS (DK) | 2010-12-29 | — | — | EP | claimed |
| WO-2010117346-A2 | STABLE PHARMACEUTICAL COMPOSITIONS WITH HIGH BIOAVAILIBILITY | BILGIC MAHMUT (TR) | 2010-10-14 | — | — | WO | claimed |
| US-20060216358-A1 | Controlled release composition containing a strontium salt | OSTEOLOGIX A/S (DK) | 2006-09-28 | — | — | US | claimed |
| EP-1622630-A2 | STRONTIUM COMBINATIONS FOR THE PROPHYLAXIS/TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS | Osteologix A/S (DK) | 2006-02-08 | — | — | EP | claimed |
| EP-1622629-A2 | CONTROLLED RELEASE COMPOSITION CONTAINING A STRONTIUM SALT | Osteologix A/S (DK) | 2006-02-08 | — | — | EP | claimed |
| WO-2005123193-A2 | TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005123130-A2 | IMPROVED TREATMENTS OF RHEUMATIC AND ARTHRITIC DISEASES COMPRISING COMBINATIONS OF A 5-LIPOXYGENASE INHIBITOR | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005123192-A2 | IMPROVING PAIN TREATMENT WITH STRONTIUM COMBINATIONS | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005123098-A2 | PREVENTING GASTROINTESTINAL SIDE-EFFECTS WITH STRONTIUM SALTS | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005082385-A1 | STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS | OSTEOLOGIX A/S (DK) | 2005-09-09 | — | — | WO | claimed |
| WO-2004098618-A2 | STRONTIUM COMBINATIONS FOR PROPHYLAXIS/TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS | OSTEOLOGIX A/S (DK) | 2004-11-18 | — | — | WO | claimed |
| WO-2004098617-A2 | CONTROLLED RELEASE COMPOSITION CONTAINING A STRONTIUM SALT | OSTEOLOGIX A/S (DK) | 2004-11-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | CA1 2089/4885HDAC3 2064/4885HDAC1 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.